Neuralink

Neuralink Valuation and Overview

Neuralink

Sectors

Health, BioTech

Headquarters

Fremont, California, USA

CEO

Elon Musk

Neuralink raised $280.0M in a Series D at a $19.03 price per share, amounting to a post-money valuation of $5.0B on August 1, 2023. PM Insights data indicates that Neuralink's shares have been trading at an 154.49% premium to their Series D Valuation based on institutional secondary market activity.

Register today to view the full report, with more in-depth details and analytics

Series D Valuation

Latest funding round

$5.0B

XXXXX

2023-08-01

XX-XX-XXXX

AV Implied Valuation

$12.72B

2025-02-24

AV Implied Valuation

XXXXX

XX-XX-XXXX

Change since Last Round

154.49%

2023-08-01 ➞ 2025-02-24

Change since Last Round

XXXXX

XX-XX-XXXX

Secondary Activity

Medium

XXXXX

Volume

114.58M

XXX

(90 day period)

Bid

XXX

Ask

XXX

Bid

89.58M

Ask

25.0M

Neuralink Research

Contrary - Neuralink

Neuralink News

February 23, 2025

FDA Rehires Scientists After Mass Firings, Including Neuralink Reviewers

The FDA is rehiring scientists, including Neuralink reviewers, after mass firings, raising concerns about stability and compensation in the agency.

February 22, 2025

Elon Musk chooses Miami for Neuralink brain-implant research

Neuralink has chosen Miami for its PRIME Study, focusing on brain-computer interfaces to assist patients with paralysis and ALS.

February 22, 2025

FDA Rehiring Furloughed Scientists Amid Neuralink Trial Controversy

The FDA is rehiring scientists to enhance the review process for Neuralink's clinical trials, which have recently been approved despite prior safety concerns.

Register today to view the full report, with more in-depth details and analytics:

Access the full report

Register today to view the full Neuralink report, with more in-depth details and analytics:

Access the full Neuralink report

Ready to see it in action?

Schedule a demo with one of our experts